How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Doug Mahoney Doug Mahoney is a writer covering home-improvement topics, ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Marshall Hargrave is a stock analyst and writer with 10+ years of experience covering stocks and markets, as well as analyzing and valuing companies. Thomas J. Brock is a CFA and CPA with more than 20 ...

Have you ever heard of FINDSTR and Select-String? Select-String is a cmdlet that is used to search text & the patterns in input strings & files. It is similar to grep on Linux & FINDSTR on Windows. In ...

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.